
Veradermics Inc
MANEHealthcare|Biotechnology|USA
$119.60
-5.31 (-4.25%)
Tangible Book
$10.46
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
12.99,
57.33,
226.67,
528.87
],
"ebit_estimate": [
-117.44,
-124.12,
-82.84,
-14.1,
235
],
"ebitda_estimate": [
-118.71,
-129.3,
131.7,
null,
null
],
"net_income_estimate": [
-111.07,
-118.87,
-131.13,
-9.63,
240.63
],
"per_share_eps_estimate": [
-2.94,
-2.64,
-2.86,
-0.28,
5.14
],
"eps_nri_estimate": [
-2.99,
-2.69,
-2.8,
-0.14,
5.23
],
"dividend_estimate": [
5.55,
5.55,
5.55,
11.1,
11.1
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-101.87,
-115.03,
-74.55,
-11.63,
231.93
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
-85.01,
-21.36,
12.2,
null,
null
],
"gross_margin_estimate": [
null,
null,
90,
92.5,
92.5
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
23.27
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -21.54,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"ebit_estimate": [
-29.59,
-29,
-28.97,
-24,
-28,
-30,
-39
],
"ebitda_estimate": [
-27.93,
-29.68,
-31.24,
null,
null,
null,
null
],
"net_income_estimate": [
-27.99,
-26.84,
-26.95,
-22,
-25,
-28,
-37
],
"per_share_eps_estimate": [
-0.61,
-0.56,
-0.58,
-0.53,
-0.6,
-0.66,
-0.89
],
"eps_nri_estimate": [
-0.67,
-0.63,
-0.63,
-0.53,
-0.6,
-0.66,
-0.89
],
"dividend_estimate": [
2.8,
2.8,
2.8,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-25.77,
-24.8,
-25.93,
-22,
-25,
-28,
-37
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -21.54,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}